Sativex Satisfies Regulatory Hurdle, UK

February 25, 2009 at 8:00 am Leave a comment

The makers of cannabis-based treatment Sativex have today reported the results of a trial held to establish how effective the therapy is in people with multiple sclerosis (MS).

GW Pharmaceuticals were asked by the Medicines and Healthcare Regulatory Authority (MHRA) to hold the withdrawal study, which evaluated 36 people with spasticity and who had previously been taking Sativex on prescription.

This group was divided into two, with one continuing to take Sativex, the other being given placebo.

Today’s results show that in those people given placebo over four weeks, symptoms of spasticity worsened, but that there was no evidence of an adverse reaction to having the treatment withdrawn.

Dr Lee Dunster, Head of Research at the MS Society, said: “We know from our members that there is huge interest in how this drug performs in trials.

“These latest results satisfy a necessary hurdle with the drug regulators and we’re looking forward to seeing data from the larger trial that will show how effective it is in greater numbers of people.”

MS Society



Entry filed under: Uncategorized.

Agenda For Research On Chernobyl Health: Chernobyl Public Health Research Coordinated By IARC Government’s GP Extended Opening Policy Widens Rich-Poor Gap, United Kingdom

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Blog Stats

  • 15,733 hits

%d bloggers like this: